LRMR
Larimar Therapeutics Inc (LRMR)
Healthcare • NASDAQ • $3.97-0.75%
Key Fundamentals
- Symbol
- LRMR
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $3.97
- Daily Change
- -0.75%
- Market Cap
- $412.42M
- Trailing P/E
- N/A
- Forward P/E
- -2.41
- 52W High
- $6.42
- 52W Low
- $1.73
- Analyst Target
- $16.22
- Dividend Yield
- N/A
- Beta
- 0.91
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Company websiteResearch LRMR on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.